Brady Grainer, CEO of BioCorRX Inc. Joins Everett Jolly on “Stock Day”
PHOENIX, Ariz., July 24, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire, today announced the return of BradyGrainer, CEO of BioCorRX Inc. to Uptick Newswire’s Stock Day podcast with Everett Jolly. The Company is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions.
The first component of their program is an outpatient implant procedure, to insert an implant that delivers the non-addictive medicine, naltrexone which is used to treat opioid and alcohol use disorders.“This product is really incredible, it is and opioid antagonist that can significantly reduce physical cravings for alcohol and opioids,” said Jolly. “Where are you at in the FDA process?”
“After our meeting with the FDA in January we have a better understanding of how to move forward,” explainedGrainer. “We are now waiting for our NIDA grant review, in the meantime we are doing some behind the scenes work for the development plan.”
“BioCorRX recently raised $1.1 million, what does that mean for the Company and what are you going to do with those funds?” asked Jolly.
“Our spending is primarily focused on the R&D of our BICX102 product,” continued Grainer. “We have a product that works and with the FDA approval we will have a larger market. Management is working to build a strong Company which in turn will increase value for our shareholders.”
To listen to the full interview please click here to the following link:
About BioCorRx
BioCorRx Inc. (OTCQB:BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of the use of sustained release naltrexone, usually in implantable form and under the direction and care of an independent licensed physician. Implant forms of naltrexone deliver the non-addictive medicine which is an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, as well as some of their effects. The second component of the program developed by BioCorRx Inc. is a proprietary cognitive behavioral therapy (CBT) program specifically tailored for the treatment of alcohol and opioid use disorders for those receiving sustain release naltrexone treatment. The behavioral portion of the program also includes overlapping peer recovery support and tracking. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit .
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and its sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the video interview Studio located in Phoenix, Arizona.
Source: Uptick Newswire
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at
